The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...

In a first-in-human phase 1/2a clinical trial, researchers used adult stem cells to help restore vision in people with age-related macular degeneration. In the United States, age-related macular degen ...

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect ...

Coave Therapeutics has announced its lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, ...

NEWTON, Mass.--(BUSINESS WIRE)--Inflammasome Therapeutics (https://inflam.com), a private company developing therapies for prevalent, degenerative diseases, said ...

An international collaboration of scientists publishing in Nature Reviews Disease Primers this week advocate for a new way of thinking about and finding treatments for age-related macular degeneration ...

In this randomized trial of patients with age-related macular disease, eccentric viewing training failed to systematically enhance visual ability, reading performance, or fixation stability compared ...

Please provide your email address to receive an email when new articles are posted on . NEW YORK — A retrospective study of more than 36,000 patients showed that geographic atrophy causes substantial ...

The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...